Arca Biopharma Inc  

(Public, NASDAQ:ABIO)   Watch this stock  
Find more results for ABIO
+0.14 (2.41%)
Nov 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.57 - 5.99
52 week 4.51 - 10.85
Open 5.76
Vol / Avg. 187,080.00/93,421.00
Mkt cap 52.50M
P/E     -
Div/yield     -
EPS -2.77
Shares 9.05M
Beta 1.34
Inst. own 66%
Nov 12, 2015
Q3 2015 ARCA Biopharma Inc Earnings Release
Sep 10, 2015
ARCA Biopharma Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -25.80% -58.34%
Return on average equity -26.60% -63.91%
Employees 16 -
CDP Score - -


11080 Circle Point Rd Ste 140
WESTMINSTER, CO 80020-2769
United States - Map
+1-720-9402200 (Phone)
+1-720-2089261 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator. Gencaro is being evaluated in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure and left ventricular systolic dysfunction (HFREF). Gencaro is part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF. Data from the Phase III HF trial of Gencaro in 2,708 heart failure (HF) patients, or the BEST trial, suggested that Gencaro reduces or prevents AF.

Officers and directors

Robert E. Conway Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Michael R. Bristow Ph.D., M.D. President, Chief Executive Officer, Director
Age: 70
Bio & Compensation  - Reuters
Thomas A. Keuer Chief Operating Officer
Age: 56
Bio & Compensation  - Reuters
Christopher David Ozeroff J.D. Senior Vice President, General Counsel, Secretary
Age: 56
Bio & Compensation  - Reuters
Brian L. Selby CPA Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Linda S. Grais M.D., J.D. Lead Independent Director
Age: 58
Bio & Compensation  - Reuters
Daniel J. Mitchell Director
Age: 58
Bio & Compensation  - Reuters
Raymond L. Woosley M.D., Ph.D. Director
Age: 72
Bio & Compensation  - Reuters